Maintenance rituximab for CNS lymphoma

2087 Background: Maintenance therapy with rituximab is being increasingly examined in patients with indolent non-Hodgkin's lymphoma (NHL) as a means of prolonging disease control. Patients with primary central nervous system lymphoma (PCNSL) and NHL with CNS involvement are at high risk for recurrence following response to initial or salvage therapy. The use of maintenance therapy in this patient population has not been rigorously studied. Methods: Following IRB approval, charts of patients with CD20+ CNS lymphoma receiving maintenance rituximab were retrospectively reviewed for demographics, treatment details, tumor progression and survival. Maintenance rituximab was defined as delivery of regularly scheduled rituximab following a radiographic CR to treatment for CNS lymphoma. All patients received 750mg/m2 on a monthly basis for at least one year. Results: 9 patients were identified; 6 with PCNSL and 3 with CNS relapse of systemic NHL. Median age was 59 years (range, 40–76) and median KPS was 80 (range,...